SEIZSAFE · Project

Smart Night-Time Seizure Detection Device That Alerts Caregivers and Tracks Patients via Cloud

healthPilotedTRL 8

Imagine a parent sleeping in the same room as their child with epilepsy, afraid to close their eyes because a seizure could happen any moment during the night. SEIZSAFE built a bedside device that learns each patient's unique seizure patterns, automatically detects when one is happening, and instantly alerts the caregiver — even in another room. It also records video and sends data to a cloud platform so doctors can track seizure history over time. Think of it like a smart baby monitor, but specifically tuned for epilepsy patients.

By the numbers

50 million

people worldwide with epilepsy

4-10 per 1,000

general population prevalence of active epilepsy

2.4 million

new epilepsy diagnoses per year globally

1.2 million

epilepsy patients suffering night-time seizures (global market size)

6.5%

target market share in 5 years

80,000

target users by end of 2022

The business problem

What needed solving

Epilepsy caregivers — often family members — must stay awake or sleep in the same room as patients to respond to dangerous night-time seizures, leading to exhaustion, loss of privacy, and increased patient risk. With 50 million epilepsy patients worldwide and an estimated 1.2 million experiencing night-time seizures, there is no affordable, medically validated home monitoring solution that automatically detects seizures and alerts caregivers. Current options are either too expensive, too intrusive, or unreliable.

The solution

What was built

SEIZSAFE built a CE-marked Class I medical device: a bedside seizure detection system with a self-learning algorithm that adapts to each patient, a camera for recording seizure events, caregiver alerting, and a private cloud platform for doctors to track patient data. The project delivered 6 total deliverables including the CE mark certification.

Audience

Who needs this

Medical device distributors specializing in neurology or home care equipmentResidential care homes and assisted living facilities with epilepsy patientsTelemedicine and remote patient monitoring platform providersHealth insurance companies looking for cost-effective home monitoring solutionsNational epilepsy associations and patient advocacy organizations

Business applications

Who can put this to work

Medical Device Distribution

SME

Target: Medical device distributors and home healthcare equipment suppliers

If you are a medical device distributor looking for proven products in the neurology space — this project developed a CE-marked Class I medical device that detects night-time epilepsy seizures and alerts caregivers. With approximately 50 million epilepsy patients worldwide and an estimated 1.2 million suffering night-time seizures, you would be tapping into a clearly defined market with an affordable, medically validated device.

Digital Health & Telemedicine

mid-size

Target: Telemedicine platforms and remote patient monitoring companies

If you are a telemedicine company expanding your remote monitoring capabilities — SEIZSAFE developed a cloud-connected seizure detection platform that gives doctors continuous access to patient seizure data and video recordings. The system's self-learning algorithm adapts to each patient, reducing false alarms. This could plug directly into your existing remote care offering for neurology patients.

Residential Care & Assisted Living

any

Target: Residential care homes and epilepsy care facilities

If you run a care facility where night staff must monitor residents with epilepsy — this device replaces the need for constant bedside watch with automated detection and instant alerts. With 4 to 10 per 1,000 people affected by active epilepsy, care homes typically have multiple residents needing overnight monitoring. SEIZSAFE's reduced-cost technology could lower your staffing burden while improving patient safety.

Frequently asked

Quick answers

What does this device cost and what is the pricing model?

The project emphasizes 'reduced-cost technology' as a key differentiator but does not disclose specific pricing. The system targets a global market of 1.2 million night-time seizure patients, suggesting consumer-accessible pricing. Contact the developer ENCORE LAB SL for current pricing and volume discounts.

Can this scale to serve hospitals or care networks, not just individual homes?

The cloud platform component was designed for doctor-level patient tracking and big data analysis across patient populations. This architecture supports multi-patient, multi-site deployment. The project targeted 80,000 users within 5 years of launch, indicating the system was built for scale.

What is the IP situation — can we license or white-label this technology?

SEIZSAFE was developed entirely by ENCORE LAB SL as a single-partner SME project, meaning IP ownership is concentrated with one company. The self-learning seizure detection algorithm is the core proprietary asset. Licensing or partnership inquiries should go directly to ENCORE LAB SL in Spain.

Is this device certified for medical use in Europe?

Yes. The project deliverables explicitly include a Class I medical device CE mark, which means the device can be legally sold across the European Economic Area. Class I is the standard category for low-risk monitoring devices. This is a significant regulatory milestone already cleared.

How long has this been in development and what is the current status?

The EU-funded project ran from June 2016 to February 2019 and is now closed. The project website was seizsafe.com. Since the project achieved CE marking during its funded period, the product was positioned for market entry by early 2019.

Does this integrate with existing hospital IT or electronic health record systems?

The project developed a private cloud platform for medical tracking and big data exploitation. Based on available project data, specific EHR integration details are not documented. However, the cloud-based architecture suggests API connectivity is technically feasible. Integration specifics should be discussed with the developer.

What clinical evidence supports the detection accuracy?

The project lists 'medical validation' as one of its key characteristics, and the self-learning algorithm adapts to each individual patient's seizure patterns. Based on available project data, specific accuracy percentages or clinical trial results are not disclosed in the summary. The CE marking process requires demonstration of safety and performance.

Consortium

Who built it

This is a single-company project by ENCORE LAB SL, a Spanish SME. With 100% industry composition and no university or research institute partners, the project is purely commercially driven. The absence of academic partners suggests the core technology was already developed in-house before EU funding, and the SME Instrument Phase 2 grant was used to push toward market readiness — which is confirmed by the achieved CE mark. For a business partner, this means you would deal directly with one decision-maker, simplifying licensing or distribution negotiations. The risk is that a single small company carries all development, manufacturing, and support responsibilities.

ENCORE LAB SLCoordinator · ES

How to reach the team

ENCORE LAB SL is a Spanish SME — look for the founder or CEO on LinkedIn under ENCORE LAB or SEIZSAFE.

Order a report on this consortium See ENCORE LAB SL profile →

Next steps

Talk to the team behind this work.

Want an introduction to the SEIZSAFE team? SciTransfer can connect you with the right person at ENCORE LAB SL and provide a detailed technology brief. Contact us to discuss.

Order a report on this topic More in Health & Biomedical